---
title: Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
nct_id: NCT02311907
overall_status: COMPLETED
phase: PHASE3
sponsor: Alliance for Clinical Trials in Oncology
study_type: INTERVENTIONAL
primary_condition: Chemotherapeutic Agent Toxicity
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02311907.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02311907"
ct_last_update_post_date: 2017-02-23
last_seen_at: "2026-05-12T07:20:06.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer

**Official Title:** The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study

**NCT ID:** [NCT02311907](https://clinicaltrials.gov/study/NCT02311907)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 195
- **Lead Sponsor:** Alliance for Clinical Trials in Oncology
- **Collaborators:** National Cancer Institute (NCI)
- **Conditions:** Chemotherapeutic Agent Toxicity, Neuropathy, Neurotoxicity Syndrome, Pain, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
- **Start Date:** 2009-12
- **Completion Date:** 2012-08
- **CT.gov Last Update:** 2017-02-23

## Brief Summary

This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary peritoneal cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as glutathione, may help prevent peripheral neuropathy caused by paclitaxel and carboplatin. It is not yet known whether glutathione is more effective than a placebo in preventing peripheral neuropathy.

## Detailed Description

PRIMARY OBJECTIVES:

I. To compare TAXOL (paclitaxel)/carboplatin (CBDCA) induced peripheral neuropathy as measured by European Organization for Research and Treatment of Cancer (EORTC)- Quality of Life (QOL)-chemotherapy induced peripheral neuropathy 20 (CIPN20) between glutathione (GSH) and placebo arms.

SECONDARY OBJECTIVES:

I. To compare the incidences of grade 2+ and grade 3+ TAXOL/CBDCA induced peripheral neuropathy measured by Common Terminology Criteria for Adverse Events (CTCAE) neuropathy scale between GSH and placebo arms.

II. To compare the time to onset of grade 2+ and grade 3+ TAXOL/CBDCA induced peripheral neuropathy between GSH and placebo arms, measured by CTCAE neuropathy scale.

III. To compare the proportion of patients requiring chemotherapy dose reductions secondary to TAXOL/CBDCA induced peripheral neuropathy between GSH and placebo arms.

IV. To compare the proportion of patients stopping TAXOL/CBDCA secondary to peripheral neuropathy between GSH and placebo arms.

V. To assess the toxicity profile of GSH in this situation. VI. To evaluate whether GSH influences the anti-tumor activity of TAXOL/CBDCA. VII. To evaluate patient quality of life (QOL) measured by Functional Assessment of Cancer Therapy-Ovarian (FACT-O) (ovarian/fallopian tube/primary peritoneal cancer patients only) and patient daily symptom questionnaires over time between GSH and placebo arms.

TERTIARY:

I. To explore the association of genetic variations in genes involved in taxane/platinum metabolism with incidence of grade 2+ TAXOL/CBDCA induced peripheral neuropathy.

II. As part of ongoing research for North Central Cancer Treatment Group (NCCTG) studies, we are banking blood products for future studies.

OUTLINE:

Patients are stratified according to baseline neuropathy (none vs grade 1), debulked status (no gross residual disease \[no clinically apparent residual lesions at the completion of primary surgery\] vs optimal \[largest residual lesion \< 1 cm at primary surgery\] vs sub-optimally debulked \[residual lesion \> 1 cm\] or not operated upon), and cancer type (ovarian/fallopian tube/primary peritoneal cancers vs lung cancer vs other). Patients are randomized to 1 of 2 treatment arms. Patients are grouped based on, Planned paclitaxel dose cycle length (Weekly vs. every 3 weeks vs. every 4 weeks). The stratification factors listed include demographic, prognostic factors and medication that can potentially impact the primary or secondary outcomes, so they need to be distributed evenly among the two arms. The 18 level combinations involved in these four stratification factors are within the maximum recommended of one half of the group sample size for the study.

Ideally, patients begin receiving glutathione before their first dose of chemotherapy, but must begin glutathione before their second dose of chemotherapy.

ARM I: Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel\* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.

ARM II: Patients receive placebo IV over 15 minutes, paclitaxel\* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.

NOTE: \*Alternatively, patients may receive paclitaxel IV over 1 hour and glutathione/placebo IV over 15 minutes weekly and carboplatin every 21 days for 12 weeks.

Blood samples are collected periodically for pharmacogenomic and other biomarker analyses. Patients complete questionnaires periodically, including quality-of-life assessments.

After completion of study treatment, patients are followed up every 3 months for 1 year.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Scheduled to undergo treatment with TAXOL at 150-200 mg/m2 and CBDCA at area under the curve (AUC) = 5-7 every 21 or 28 days for at least 12 weeks; alternatively, paclitaxel can be prescribed at 80 mg/m2 weekly for at least 12 weeks, with the same CBDCA dose of AUC = 5-7 every 21 days; additional chemotherapy agents are allowed (bevacizumab, etoposide, etc) per physician discretion, as long as they are not known to be neurotoxic; Note: patients ideally will begin GSH therapy prior to their first dose of this chemotherapy, but must begin GSH therapy prior to their second dose of chemotherapy
* Ability to sign informed consent and understand the nature of a placebo-controlled trial
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Ability to complete English language questionnaire(s) by themselves or with assistance
* Life expectancy \>= 6 months
* Negative pregnancy test done =\< 7 days prior to registration, for women of childbearing potential only, per clinician discretion
* Willingness to provide blood specimens as required by the protocol
* White blood cell (WBC) \>= 3400
* Absolute neutrophil count (ANC) \>= 1500
* Platelet (PLT) \>= 100,000
* Hemoglobin (HgB) \> 10.0
* Creatinine =\< 1.5 x upper limit of normal (ULN)

Exclusion Criteria:

* Pre-existing history of peripheral neuropathy \> grade 1 (National Cancer Institute \[NCI\] CTCAE version \[v\] 4.0) due to any cause (e.g., chemotherapy, diabetes, alcohol, toxin, or heredity)
* Other medical conditions, which in the opinion of the treating physician/allied health professional would make this protocol unreasonably hazardous for the patient
* Any of the following:

  * Pregnant women
  * Nursing women
  * Women of childbearing potential who are unwilling to employ adequate contraception
* Prior TAXOL and/or CBDCA chemotherapy treatment (other than the current treatment regimen)
* Concurrent use of any agent being used specifically to prevent or treat neuropathy, including but not limited to the following:

  * Gabapentin
  * Glutamine powder or glutamine tablets
  * Vitamin B6 or E
```

## Arms

- **Arm I (glutathione, carboplatin)** (EXPERIMENTAL) — Patients receive glutathione intravenously (IV) over 15 minutes, paclitaxel\* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.
- **Arm II (placebo, paclitaxel)** (PLACEBO_COMPARATOR) — Patients receive placebo IV over 15 minutes, paclitaxel\* IV over 1 or 3 hours depending on planned dose cycle length and carboplatin IV over 30 minutes.

## Interventions

- **Carboplatin** (DRUG) — Given IV, over 30 minutes per planned chemotherapy regimen
- **Glutathione** (DRUG) — Given IV, over 15 minutes, immediately before chemotherapy administration
- **Laboratory Biomarker Analysis** (OTHER) — Correlative studies
- **Paclitaxel** (DRUG) — Given IV, over 1 or 3 hours, per planned chemotherapy regimen
- **Placebo** (OTHER) — Given IV
- **Quality-of-Life Assessment** (OTHER) — Ancillary studies

## Primary Outcomes

- **Paclitaxel/Carboplatin (PC) Induced Peripheral Neuropathy as Assessed by EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer (EORTC), Quality of Life (QLQ), Chemotherapy Induced Peripheral Neuropathy 20 (CIPN20)).** _(time frame: Every 28 day cycle, up to 6 cycles.)_ — The CIPN sensory subscale will be calculated by standard scoring algorithm and converted to 0-100 scale (higher scores indicated less symptoms and better quality of life). Generalized linear models (repeated measures analysis of variance \[ANOVA\] if data are complete) will be used to compare the CIPN between Glutathione (GSH) and placebo arms.

## Secondary Outcomes

- **Recurrence-free Survival (for Patients Without Clinical Evidence of Disease)** _(time frame: Up to 1 year)_
- **Change in Patient Reported Quality of Life as Assessed by Functional Assessment of Cancer Therapy-Ovarian (FACT-O) and Patient Daily-symptom Questionnaires Over Time.** _(time frame: Baseline to 1 year)_
- **Paclitaxel Acute Pain Syndrome Incidence and Severity Between GSH and Placebo Arms** _(time frame: Up to 1 year)_
- **Percentage of Patients Delaying PC Chemotherapy Secondary to PN** _(time frame: Up to 1 year)_
- **Percentage of Patients Undergoing Dose Reductions Secondary to PCI PN** _(time frame: Up to 1 year)_
- **Percentage of Patients With Grade 2+ and Grade 3+ Paclitaxel/Carboplatin-induced (PCI) Peripheral Neuropathy (PN) According to the Common Terminology Criteria for Adverse Events (CTCAE) Neuropathy Scale** _(time frame: Up to 1 year)_
- **Times to Onset of CTCAE Grade 2+ PN** _(time frame: Up to 1 year)_
- **Times to Onset of CTCAE Grade 3+ PN** _(time frame: Up to 5 years from registration)_

## Locations (390)

- Providence Hospital, Mobile, Alabama, United States
- Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
- Northbay Cancer Center, Fairfield, California, United States
- Cancer Care Associates of Fresno Medical Group Inc, Fresno, California, United States
- Saint Joseph Hospital - Orange, Orange, California, United States
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
- Feather River Cancer Center, Paradise, California, United States
- Sutter Roseville Medical Center, Roseville, California, United States
- Sutter General Hospital, Sacramento, California, United States
- The Medical Center of Aurora, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Penrose-Saint Francis Healthcare, Colorado Springs, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Exempla Saint Joseph Hospital, Denver, Colorado, United States
- Presbyterian - Saint Lukes Medical Center - Health One, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- Colorado Cancer Research Program CCOP, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- Poudre Valley Hospital, Fort Collins, Colorado, United States
- Front Range Cancer Specialists, Fort Collins, Colorado, United States
- Saint Mary's Hospital and Regional Medical Center, Grand Junction, Colorado, United States
- North Colorado Medical Center, Greeley, Colorado, United States
- Saint Anthony Hospital, Lakewood, Colorado, United States
- Sky Ridge Medical Center, Lone Tree, Colorado, United States
- Longmont United Hospital, Longmont, Colorado, United States
- McKee Medical Center, Loveland, Colorado, United States
- Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
- North Suburban Medical Center, Thornton, Colorado, United States
- Exempla Lutheran Medical Center, Wheat Ridge, Colorado, United States
- Greenwich Hospital, Greenwich, Connecticut, United States
- Saint Francis Hospital and Medical Center, Hartford, Connecticut, United States
- Halifax Health Medical Center-Centers for Oncology, Daytona Beach, Florida, United States
- Mayo Clinic in Florida, Jacksonville, Florida, United States
- Phoebe Putney Memorial Hospital, Albany, Georgia, United States
- Piedmont Hospital, Atlanta, Georgia, United States
- Atlanta Regional CCOP, Atlanta, Georgia, United States
- Northside Hospital, Atlanta, Georgia, United States
- Saint Joseph's Hospital of Atlanta, Atlanta, Georgia, United States
- Georgia Regents University Medical Center, Augusta, Georgia, United States
- Well Star Cobb Hospital, Austell, Georgia, United States
- John B Amos Cancer Center, Columbus, Georgia, United States
- Dekalb Medical Center, Decatur, Georgia, United States
- Northeast Georgia Medical Center, Gainesville, Georgia, United States
- Gwinnett Medical Center, Lawrenceville, Georgia, United States
- Wellstar Kennestone Hospital, Marietta, Georgia, United States
- Southern Regional Medical Center, Riverdale, Georgia, United States
- Harbin Clinic Medical Oncology and Clinical Research, Rome, Georgia, United States
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
- Oncare Hawaii Inc-POB II, Honolulu, Hawaii, United States
- Queen's Medical Center, Honolulu, Hawaii, United States
- Straub Clinic and Hospital, Honolulu, Hawaii, United States
- University of Hawaii Cancer Center, Honolulu, Hawaii, United States
- Oncare Hawaii Inc-Kuakini, Honolulu, Hawaii, United States
- The Cancer Center of Hawaii-Liliha, Honolulu, Hawaii, United States
- Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States
- Castle Medical Center, Kailua, Hawaii, United States
- Wilcox Memorial Hospital and Kauai Medical Clinic, Lihue, Hawaii, United States
- Maui Memorial Medical Center, Wailuku, Hawaii, United States
- Pacific Cancer Institute of Maui, Wailuku, Hawaii, United States
- Pali Momi Medical Center, ‘Aiea, Hawaii, United States
- Saint Joseph Medical Center, Bloomington, Illinois, United States
- Illinois CancerCare-Bloomington, Bloomington, Illinois, United States
- Graham Hospital Association, Canton, Illinois, United States
- Illinois CancerCare-Canton, Canton, Illinois, United States
- Illinois CancerCare-Carthage, Carthage, Illinois, United States
- Memorial Hospital, Carthage, Illinois, United States
- Presence Resurrection Medical Center, Chicago, Illinois, United States
- Decatur Memorial Hospital, Decatur, Illinois, United States
- Eureka Hospital, Eureka, Illinois, United States
- Illinois CancerCare-Eureka, Eureka, Illinois, United States
- Illinois CancerCare Galesburg, Galesburg, Illinois, United States
- Ingalls Memorial Hospital, Harvey, Illinois, United States
- Illinois CancerCare-Havana, Havana, Illinois, United States
- Mason District Hospital, Havana, Illinois, United States
- Illinois CancerCare-Kewanee Clinic, Kewanee, Illinois, United States
- Adventist La Grange Memorial Hospital, La Grange, Illinois, United States
- Illinois CancerCare-Macomb, Macomb, Illinois, United States
- Mcdonough District Hospital, Macomb, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- Garneau, Stewart C MD (UIA Investigator), Moline, Illinois, United States
- Porubcin, Michael MD (UIA Investigator), Moline, Illinois, United States
- Sharis, Christine M MD (UIA Investigator), Moline, Illinois, United States
- Spector, David MD (UIA Investigator), Moline, Illinois, United States
- Stoffel, Thomas J MD (UIA Investigator), Moline, Illinois, United States
- Trinity Medical Center, Moline, Illinois, United States
- Holy Family Medical Center, Monmouth, Illinois, United States
- Illinois CancerCare-Monmouth, Monmouth, Illinois, United States
- Bromenn Regional Medical Center, Normal, Illinois, United States
- Community Cancer Center Foundation, Normal, Illinois, United States
- Illinois CancerCare-Community Cancer Center, Normal, Illinois, United States
- Illinois CancerCare-Ottawa Clinic, Ottawa, Illinois, United States
- Ottawa Regional Hospital and Healthcare Center, Ottawa, Illinois, United States
- Illinois CancerCare-Pekin, Pekin, Illinois, United States
- Pekin Cancer Treatment Center, Pekin, Illinois, United States
- Pekin Hospital, Pekin, Illinois, United States
- Methodist Medical Center of Illinois, Peoria, Illinois, United States
- Proctor Hospital, Peoria, Illinois, United States
- OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC, Peoria, Illinois, United States
- Illinois CancerCare-Peoria, Peoria, Illinois, United States
- Illinois Oncology Research Association CCOP, Peoria, Illinois, United States
- OSF Saint Francis Medical Center, Peoria, Illinois, United States
- Illinois CancerCare-Peru, Peru, Illinois, United States
- Illinois Valley Hospital, Peru, Illinois, United States
- Valley Radiation Oncology, Peru, Illinois, United States
- Illinois CancerCare-Princeton, Princeton, Illinois, United States
- Perry Memorial Hospital, Princeton, Illinois, United States
- Illinois CancerCare-Spring Valley, Spring Valley, Illinois, United States
- Saint Margaret's Hospital, Spring Valley, Illinois, United States
- Memorial Medical Center, Springfield, Illinois, United States
- Carle Cancer Center, Urbana, Illinois, United States
- Franciscan St. Francis Health-Beech Grove, Beech Grove, Indiana, United States
- Elkhart Clinic, Elkhart, Indiana, United States
- Michiana Hematology Oncology PC-Elkhart, Elkhart, Indiana, United States
- Elkhart General Hospital, Elkhart, Indiana, United States
- Community Howard Regional Health, Kokomo, Indiana, United States
- IU Health La Porte Hospital, La Porte, Indiana, United States
- IU Health Arnett Cancer Care, Lafayette, Indiana, United States
- Franciscan Saint Anthony Health-Michigan City, Michigan City, Indiana, United States
- Michiana Hematology Oncology PC-Mishawaka, Mishawaka, Indiana, United States
- Saint Joseph Regional Medical Center-Mishawaka, Mishawaka, Indiana, United States
- Michiana Hematology Oncology PC-Plymouth, Plymouth, Indiana, United States
- Reid Hospital and Health Care Services, Richmond, Indiana, United States
- Memorial Hospital of South Bend, South Bend, Indiana, United States
- Michiana Hematology Oncology PC-South Bend, South Bend, Indiana, United States
- South Bend Clinic, South Bend, Indiana, United States
- Northern Indiana Cancer Research Consortium CCOP, South Bend, Indiana, United States
- Michiana Hematology Oncology PC-Westville, Westville, Indiana, United States
- McFarland Clinic PC-William R Bliss Cancer Center, Ames, Iowa, United States
- Constantinou, Costas L MD (UIA Investigator), Bettendorf, Iowa, United States
- Hematology Oncology Associates-Quad Cities, Bettendorf, Iowa, United States
- Cedar Rapids Oncology Association, Cedar Rapids, Iowa, United States
- Mercy Hospital, Cedar Rapids, Iowa, United States
- Oncology Associates at Mercy Medical Center, Cedar Rapids, Iowa, United States
- Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa, United States
- Iowa Methodist Medical Center, Des Moines, Iowa, United States
- Iowa Oncology Research Association CCOP, Des Moines, Iowa, United States
- Medical Oncology and Hematology Associates-Des Moines, Des Moines, Iowa, United States
- Medical Oncology and Hematology Associates-Laurel, Des Moines, Iowa, United States
- Mercy Medical Center - Des Moines, Des Moines, Iowa, United States
- Iowa Lutheran Hospital, Des Moines, Iowa, United States
- Ottumwa Regional Health Center, Ottumwa, Iowa, United States
- Siouxland Regional Cancer Center, Sioux City, Iowa, United States
- Mercy Medical Center-Sioux City, Sioux City, Iowa, United States
- Saint Luke's Regional Medical Center, Sioux City, Iowa, United States
- Cancer Center of Kansas - Chanute, Chanute, Kansas, United States
- Cancer Center of Kansas - Dodge City, Dodge City, Kansas, United States
- Cancer Center of Kansas - El Dorado, El Dorado, Kansas, United States
- Cancer Center of Kansas - Fort Scott, Fort Scott, Kansas, United States
- Cancer Center of Kansas-Independence, Independence, Kansas, United States
- Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
- Lawrence Memorial Hospital, Lawrence, Kansas, United States
- Cancer Center of Kansas-Liberal, Liberal, Kansas, United States
- Cancer Center of Kansas - McPherson, McPherson, Kansas, United States
- Cancer Center of Kansas - Newton, Newton, Kansas, United States
- Menorah Medical Center, Overland Park, Kansas, United States
- Saint Luke's South Hospital, Overland Park, Kansas, United States
- Cancer Center of Kansas - Parsons, Parsons, Kansas, United States
- Kansas City CCOP, Prairie Village, Kansas, United States
- Cancer Center of Kansas - Pratt, Pratt, Kansas, United States
- Cancer Center of Kansas - Salina, Salina, Kansas, United States
- Cancer Center of Kansas - Wellington, Wellington, Kansas, United States
- Associates In Womens Health, Wichita, Kansas, United States
- Cancer Center of Kansas-Wichita Medical Arts Tower, Wichita, Kansas, United States
- Cancer Center of Kansas - Main Office, Wichita, Kansas, United States
- Via Christi Regional Medical Center, Wichita, Kansas, United States
- Wichita CCOP, Wichita, Kansas, United States
- Cancer Center of Kansas - Winfield, Winfield, Kansas, United States
- Doctors Carrol, Sheth, Raghavan, Louisville, Kentucky, United States
- Ochsner Health Center-Summa, Baton Rouge, Louisiana, United States
- Ochsner Health Center-Covington, Covington, Louisiana, United States
- Louisiana State University Sciences Center- Monroe, Monroe, Louisiana, United States
- Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States
- Louisiana State University Health Sciences Center Shreveport, Shreveport, Louisiana, United States
- Highland Clinic, Shreveport, Louisiana, United States
- Harold Alfond Center for Cancer Care, Augusta, Maine, United States
- Eastern Maine Medical Center, Bangor, Maine, United States
- The Memorial Hospital at Easton, Easton, Maryland, United States
- Cancer Trials Support Unit, Rockville, Maryland, United States
- Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States
- Michigan Cancer Research Consortium CCOP, Ann Arbor, Michigan, United States
- Oakwood Hospital and Medical Center, Dearborn, Michigan, United States
- Saint John Hospital and Medical Center, Detroit, Michigan, United States
- Green Bay Oncology - Escanaba, Escanaba, Michigan, United States
- Hurley Medical Center, Flint, Michigan, United States
- Genesys Regional Medical Center-West Flint Campus, Flint, Michigan, United States
- Green Bay Oncology - Iron Mountain, Iron Mountain, Michigan, United States
- Allegiance Health, Jackson, Michigan, United States
- Borgess Medical Center, Kalamazoo, Michigan, United States
- Bronson Methodist Hospital, Kalamazoo, Michigan, United States
- West Michigan Cancer Center, Kalamazoo, Michigan, United States
- Sparrow Hospital, Lansing, Michigan, United States
- Saint Mary Mercy Hospital, Livonia, Michigan, United States
- McLaren-Macomb, Mount Clemens, Michigan, United States
- Michiana Hematology Oncology PC-Niles, Niles, Michigan, United States
- Saint Joseph Mercy Oakland, Pontiac, Michigan, United States
- Saint Joseph Mercy Port Huron, Port Huron, Michigan, United States
- Saint Mary's of Michigan, Saginaw, Michigan, United States
- Lakeland Hospital, Saint Joseph, Michigan, United States
- Marie Yeager Cancer Center, Saint Joseph, Michigan, United States
- _and 190 more_

## Recent Field Changes (last 30 days)

- `locations.mercy hospital|coon rapids|minnesota|united states` — added _(2026-05-12)_
- `locations.essentia health cancer center|duluth|minnesota|united states` — added _(2026-05-12)_
- `locations.essentia health saint mary's medical center|duluth|minnesota|united states` — added _(2026-05-12)_
- `locations.miller-dwan hospital|duluth|minnesota|united states` — added _(2026-05-12)_
- `locations.fairview-southdale hospital|edina|minnesota|united states` — added _(2026-05-12)_
- `locations.unity hospital|fridley|minnesota|united states` — added _(2026-05-12)_
- `locations.hutchinson area health care|hutchinson|minnesota|united states` — added _(2026-05-12)_
- `locations.mayo clinic health systems-mankato|mankato|minnesota|united states` — added _(2026-05-12)_
- `locations.minnesota oncology hematology pa-maplewood|maplewood|minnesota|united states` — added _(2026-05-12)_
- `locations.saint john's hospital - healtheast|maplewood|minnesota|united states` — added _(2026-05-12)_
- `locations.abbott-northwestern hospital|minneapolis|minnesota|united states` — added _(2026-05-12)_
- `locations.hennepin county medical center|minneapolis|minnesota|united states` — added _(2026-05-12)_
- `locations.minneapolis veterans medical center|minneapolis|minnesota|united states` — added _(2026-05-12)_
- `locations.north memorial medical health center|robbinsdale|minnesota|united states` — added _(2026-05-12)_
- `locations.mayo clinic|rochester|minnesota|united states` — added _(2026-05-12)_
- `locations.coborn cancer center at saint cloud hospital|saint cloud|minnesota|united states` — added _(2026-05-12)_
- `locations.saint cloud hospital|saint cloud|minnesota|united states` — added _(2026-05-12)_
- `locations.metro-minnesota nci community oncology research program|saint louis park|minnesota|united states` — added _(2026-05-12)_
- `locations.park nicollet clinic - saint louis park|saint louis park|minnesota|united states` — added _(2026-05-12)_
- `locations.regions hospital|saint paul|minnesota|united states` — added _(2026-05-12)_
- `locations.united hospital|saint paul|minnesota|united states` — added _(2026-05-12)_
- `locations.saint francis regional medical center|shakopee|minnesota|united states` — added _(2026-05-12)_
- `locations.lakeview hospital|stillwater|minnesota|united states` — added _(2026-05-12)_
- `locations.ridgeview medical center|waconia|minnesota|united states` — added _(2026-05-12)_
- `locations.rice memorial hospital|willmar|minnesota|united states` — added _(2026-05-12)_
- `locations.minnesota oncology and hematology pa-woodbury|woodbury|minnesota|united states` — added _(2026-05-12)_
- `locations.saint luke's cancer institute|kansas city|missouri|united states` — added _(2026-05-12)_
- `locations.saint luke's hospital of kansas city|kansas city|missouri|united states` — added _(2026-05-12)_
- `locations.saint joseph health center|kansas city|missouri|united states` — added _(2026-05-12)_
- `locations.north kansas city hospital|kansas city|missouri|united states` — added _(2026-05-12)_
- `locations.heartland hematology and oncology associates incorporated|kansas city|missouri|united states` — added _(2026-05-12)_
- `locations.research medical center|kansas city|missouri|united states` — added _(2026-05-12)_
- `locations.saint luke's east - lee's summit|lee's summit|missouri|united states` — added _(2026-05-12)_
- `locations.liberty hospital|liberty|missouri|united states` — added _(2026-05-12)_
- `locations.liberty radiation oncology center|liberty|missouri|united states` — added _(2026-05-12)_
- `locations.heartland regional medical center|saint joseph|missouri|united states` — added _(2026-05-12)_
- `locations.saint joseph oncology inc|saint joseph|missouri|united states` — added _(2026-05-12)_
- `locations.cancer research for the ozarks ncorp|springfield|missouri|united states` — added _(2026-05-12)_
- `locations.mercy hospital springfield|springfield|missouri|united states` — added _(2026-05-12)_
- `locations.coxhealth south hospital|springfield|missouri|united states` — added _(2026-05-12)_
- `locations.montana cancer consortium ccop|billings|montana|united states` — added _(2026-05-12)_
- `locations.northern rockies radiation oncology center|billings|montana|united states` — added _(2026-05-12)_
- `locations.saint vincent healthcare|billings|montana|united states` — added _(2026-05-12)_
- `locations.frontier cancer center and blood institute-billings|billings|montana|united states` — added _(2026-05-12)_
- `locations.billings clinic cancer center|billings|montana|united states` — added _(2026-05-12)_
- `locations.bozeman deaconess cancer center|bozeman|montana|united states` — added _(2026-05-12)_
- `locations.bozeman deaconess hospital|bozeman|montana|united states` — added _(2026-05-12)_
- `locations.saint james community hospital and cancer treatment center|butte|montana|united states` — added _(2026-05-12)_
- `locations.benefis healthcare- sletten cancer institute|great falls|montana|united states` — added _(2026-05-12)_
- `locations.berdeaux, donald md (uia investigator)|great falls|montana|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02311907.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02311907*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*